➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
Boehringer Ingelheim
Merck
McKesson

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XTANDI

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Xtandi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00510718 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Active, not recruiting Medivation, Inc. Phase 1 2007-07-01 This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Medivation, Inc. Phase 2 2011-05-01 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
NCT01302041 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Active, not recruiting Astellas Pharma Inc Phase 2 2011-05-01 To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xtandi

Condition Name

Condition Name for Xtandi
Intervention Trials
Prostate Cancer 31
Stage IV Prostate Cancer 13
Metastatic Prostate Carcinoma 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xtandi
Intervention Trials
Prostatic Neoplasms 97
Adenocarcinoma 15
Carcinoma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xtandi

Trials by Country

Trials by Country for Xtandi
Location Trials
United States 335
Canada 42
United Kingdom 33
Spain 30
France 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xtandi
Location Trials
California 25
New York 23
Texas 20
Maryland 17
Illinois 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xtandi

Clinical Trial Phase

Clinical Trial Phase for Xtandi
Clinical Trial Phase Trials
Phase 4 8
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xtandi
Clinical Trial Phase Trials
Recruiting 57
Not yet recruiting 27
Active, not recruiting 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xtandi

Sponsor Name

Sponsor Name for Xtandi
Sponsor Trials
Medivation, Inc. 40
Astellas Pharma Inc 27
National Cancer Institute (NCI) 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xtandi
Sponsor Trials
Industry 121
Other 89
NIH 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Moodys
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.